The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


The Journal of Immunology, 2007, 179: 4415-4423.
Copyright © 2007 by The American Association of Immunologists, Inc.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yoshimoto, T.
Right arrow Articles by Nakanishi, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yoshimoto, T.
Right arrow Articles by Nakanishi, K.

IL-27 Suppresses Th2 Cell Development and Th2 Cytokines Production from Polarized Th2 Cells: A Novel Therapeutic Way for Th2-Mediated Allergic Inflammation1

Tomohiro Yoshimoto2,*,{dagger}, Takayuki Yoshimoto{ddagger}, Koubun Yasuda*,{dagger}, Junichiro Mizuguchi{ddagger},§ and Kenji Nakanishi*,{dagger}

* Department of Immunology and Medical Zoology, Hyogo College of Medicine, Hyogo, Japan; {dagger} Core Research for Evolutional Science and Technology, Japan Science and Technology Corporation, Saitama, Japan; {ddagger} Intractable Immune System Disease Research Center; and § Department of Immunology, Tokyo Medical University, Tokyo, Japan

IL-27 up-regulates Th1 but down-regulates Th2 responses. However, its molecular mechanism and regulatory effects on polarized Th2 cells remain unclear. In this study, we have revealed that IL-27 inhibits Th2 cell development as well as Th2 cytokines production from already polarized Th2 cells by down-regulation of GATA-3 and up-regulation of T-bet expression simultaneously. In vivo daily IL-27 treatment for 1 wk after Leishmania major infection protects BALB/c mice from footpad swelling by diminishing parasite burden via reciprocal regulation of Th1 and Th2 responses. Furthermore, IL-27 stimulation causes marked reduction in the capacity of host mouse to mount a Th2 response against Strongyloides venezuelensis infection. Thus, IL-27-treated mice failed to develop intestinal mastocytosis after S. venezuelensis infection and exhibited a marked delay in parasite expulsion. Finally, intranasal administration of IL-27 inhibits OVA-induced airway hyperresponsiveness and inflammation in OVA-sensitized animals. Thus, IL-27 could provide us with a novel therapeutic way for treating Th2-associated diseases such as bronchial asthma.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This study was supported by a Grant-in-Aid for Scientific Research on Priority Areas and Hitech Research Center Grant from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.

2 Address correspondence and reprint requests to Dr. Tomohiro Yoshimoto, Department of Immunology and Medical Zoology, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, Japan. E-mail address: tomo{at}hyo-med.ac.jp

3 Abbreviations used in this paper: EBI3, EBV-induced gene 3; AHR, airway hyperresponsiveness; Tg, transgenic; L3, third-stage larvae; mMCP-1, mouse mast cell protease 1; Th-17, IL-17-porducing helper T.




This article has been cited by other articles:


Home page
Int ImmunolHome page
A. V. Villarino, D. Artis, J. S. Bezbradica, O. Miller, C. J. M. Saris, S. Joyce, and C. A. Hunter
IL-27R deficiency delays the onset of colitis and protects from helminth-induced pathology in a model of chronic IBD
Int. Immunol., June 1, 2008; 20(6): 739 - 752.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
Y. Kondo, T. Yoshimoto, K. Yasuda, S. Futatsugi-Yumikura, M. Morimoto, N. Hayashi, T. Hoshino, J. Fujimoto, and K. Nakanishi
Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system
Int. Immunol., June 1, 2008; 20(6): 791 - 800.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
T. Yoshimoto, N. Morishima, I. Mizoguchi, M. Shimizu, H. Nagai, S. Oniki, M. Oka, C. Nishigori, and J. Mizuguchi
Antiproliferative Activity of IL-27 on Melanoma
J. Immunol., May 15, 2008; 180(10): 6527 - 6535.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
M. Huber, V. Steinwald, A. Guralnik, A. Brustle, P. Kleemann, C. Rosenplanter, T. Decker, and M. Lohoff
IL-27 inhibits the development of regulatory T cells via STAT3
Int. Immunol., February 1, 2008; 20(2): 223 - 234.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2007 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2007 by The American Association of Immunologists, Inc. All rights reserved.